Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Application of hydrogen sulfide synthetase inhibitor PAG in preparation of medicines for treating endometriosis (EMS)

An endometrial and inhibitor technology, applied in the field of medicine, can solve problems such as dose dependence

Active Publication Date: 2018-08-10
SHANGHAI FIRST MATERNITY & INFANT HOSPITAL
View PDF2 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

This variable two-sided regulation may be dose-dependent

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of hydrogen sulfide synthetase inhibitor PAG in preparation of medicines for treating endometriosis (EMS)
  • Application of hydrogen sulfide synthetase inhibitor PAG in preparation of medicines for treating endometriosis (EMS)
  • Application of hydrogen sulfide synthetase inhibitor PAG in preparation of medicines for treating endometriosis (EMS)

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0025] Example 1 Analysis of CBS and CSE expression levels in normal endometrium and ectopic lesion tissues of EMS patients

[0026] The normal endometrial tissues and ectopic lesion tissues of EMS patients were collected, made into paraffin sections, and the expression levels of CBS and CSE were detected by immunohistochemical method. The results showed that neither the stromal cells nor the glandular epithelial cells of the normal endometrium showed significant expression of CBS; however, in ovarian endometriosis tissues, both the stromal cells and the glandular epithelial cells had high expression of CBS. Both stromal cells and glandular epithelial cells of normal endometrium and ovarian endometriosis tissues expressed CSE; while in ovarian endometriosis tissues, stromal cells and glandular epithelial cells expressed higher levels of CSE ( figure 1 ).

Embodiment 2

[0027] Example 2 Analysis of CBS and CSE expression levels in normal endometrial stromal cells and ectopic endometrial stromal cells

[0028] The endometrial tissues of control and ectopic foci of EMS patients were collected, digested with IV collagenase (Sigma) and cultured for primary isolation and culture of ESCs. to about 70%, fixed with 4% paraformaldehyde, treated with 1X-triton100 and 3% hydrogen peroxide, blocked, incubated with antibodies, and stained. The results showed that both normal endometrium stromal cells and ovarian endometriosis stromal cells expressed CBS, and the expression of ovarian endometriosis stromal cells CBS was higher than that of normal endometrium stromal cells. Both normal endometrium stromal cells and ovarian endometriosis stromal cells expressed CSE, and the expression of CSE in ovarian endometriosis stromal cells was higher than that of normal endometrium stromal cells ( figure 2 ).

Embodiment 3

[0029] Example 3 Analysis of the promoting effect of NaHS on ESC proliferation

[0030] The ESCs were isolated and cultured, then stimulated with NaHS for 24 hours, and the cell proliferation activity of the ESCs was detected by the CCK8 (Dongren Chemical Company) method (such as image 3 shown). The results showed that NaHS could promote the proliferation of normal endometrial stromal cells within a certain range.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention belongs to the technical field of medicine, and relates to application of a hydrogen sulfide synthetase inhibitor PAG in preparation of medicines for treating endometriosis (EMS). The invention evaluates the potential value of the hydrogen sulfide synthetase inhibitor PAG in the treatment of the EMS through experimental research; the results show that the expression level of hydrogensulfide synthetase CSE in the ectopic endometrium of a patient with the EMS is higher than that of the hydrogen sulfide synthetase CSE in normal endometrium, thus suggesting that hydrogen sulfide participates in the disease progression of the EMS; sodium hydrosulfide significantly promotes the proliferation of endometrial stromal cells (ESC), but the hydrogen sulfide synthetase inhibitor PAG significantly inhibits the growth of ectopic foci. The results prove that the hydrogen sulfide synthase inhibitor PAG can be used for the preparation of the medicines for treating the EMS. The invention provides a new pharmaceutical use of the hydrogen sulfide synthetase inhibitor PAG, thus providing a new method and a new idea for the clinical treatment of the EMS.

Description

technical field [0001] The invention belongs to the technical field of medicine, and relates to the application of hydrogen sulfide synthase inhibitor PAG in the preparation of medicine for treating endometriosis. In vitro experiments and in vivo animal experiments have shown that the hydrogen sulfide donor sodium hydrosulfide significantly promotes the growth of endometrial stromal cells (ESC), while the hydrogen sulfide synthase inhibitor PAG significantly inhibits the growth of ectopic foci, and PAG can be used to prepare therapeutic Medicines for endometriosis. Background technique [0002] Existing studies have shown that endometriosis (Endometriosis, EMS) is a common chronic disease characterized by complex inflammatory estrogen-dependent growth, characterized by the growth of endometrium outside the uterine cavity , affecting 6-10% of women of reproductive age, symptoms include chronic pelvic pain, dysmenorrhea and infertility, seriously affecting women's quality of ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/198A61K31/195A61P15/00
CPCA61K31/195A61K31/198A61P15/00A61K2300/00
Inventor 赵栋李明清孙静曹艳玲雷莎婷汝萍
Owner SHANGHAI FIRST MATERNITY & INFANT HOSPITAL
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com